About nucana plc - NCNA
NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
NCNA At a Glance
NuCana Plc
3 Lochside Way
Edinburgh, Midlothian EH12 9DT
| Phone | 44-131-357-1111 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -38,684,032.83 | |
| Sector | Health Technology | Employees | 12 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NCNA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.789 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.873 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.038 |
NCNA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,223,669.402 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NCNA Liquidity
| Current Ratio | 5.604 |
| Quick Ratio | 5.604 |
| Cash Ratio | 5.06 |
NCNA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -131.957 |
| Return on Equity | -192.564 |
| Return on Total Capital | -115.027 |
| Return on Invested Capital | -187.756 |
NCNA Capital Structure
| Total Debt to Total Equity | 2.779 |
| Total Debt to Total Capital | 2.704 |
| Total Debt to Total Assets | 2.266 |
| Long-Term Debt to Equity | 2.697 |
| Long-Term Debt to Total Capital | 2.624 |